JP2022515128A5 - - Google Patents
Info
- Publication number
- JP2022515128A5 JP2022515128A5 JP2021535545A JP2021535545A JP2022515128A5 JP 2022515128 A5 JP2022515128 A5 JP 2022515128A5 JP 2021535545 A JP2021535545 A JP 2021535545A JP 2021535545 A JP2021535545 A JP 2021535545A JP 2022515128 A5 JP2022515128 A5 JP 2022515128A5
- Authority
- JP
- Japan
- Prior art keywords
- exon
- mutation
- her2
- poziotinib
- tki
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862784084P | 2018-12-21 | 2018-12-21 | |
| US62/784,084 | 2018-12-21 | ||
| PCT/US2019/068153 WO2020132633A1 (en) | 2018-12-21 | 2019-12-20 | Combination therapy for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022515128A JP2022515128A (ja) | 2022-02-17 |
| JP2022515128A5 true JP2022515128A5 (https=) | 2022-12-27 |
| JP7564806B2 JP7564806B2 (ja) | 2024-10-09 |
Family
ID=71102908
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021535545A Active JP7564806B2 (ja) | 2018-12-21 | 2019-12-20 | がんの処置のための併用療法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220041751A1 (https=) |
| EP (1) | EP3897650A4 (https=) |
| JP (1) | JP7564806B2 (https=) |
| KR (1) | KR20210107023A (https=) |
| CN (1) | CN113271948B (https=) |
| AU (1) | AU2019406210A1 (https=) |
| BR (1) | BR112021011493A2 (https=) |
| CA (1) | CA3121807A1 (https=) |
| IL (1) | IL284162A (https=) |
| MA (1) | MA54559A (https=) |
| MX (1) | MX2021007554A (https=) |
| PH (1) | PH12021551276A1 (https=) |
| SG (1) | SG11202105736QA (https=) |
| WO (1) | WO2020132633A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019243738B2 (en) * | 2018-03-27 | 2024-05-30 | Board Of Regents, The University Of Texas System | Compounds with anti-tumor activity against cancer cells bearing HER2 exon 19 mutations |
| MX2021011925A (es) * | 2019-03-29 | 2021-11-03 | Univ Texas | Compuestos con actividad antitumoral contra celulas cancerigenas que portan inserciones del exon 21 del receptor 2 del factor de crecimiento epidermico humano. |
| TW202330040A (zh) * | 2021-10-14 | 2023-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗ｈｅｒ２抗體藥物偶聯物和酪胺酸激酶抑制劑聯合在製備治療腫瘤的藥物中的用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102771603B1 (ko) * | 2016-11-17 | 2025-02-24 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | Egfr 또는 her2 엑손 20 돌연변이를 갖는 암 세포에 대한 항종양 활성을 갖는 화합물 |
| AU2019243738B2 (en) * | 2018-03-27 | 2024-05-30 | Board Of Regents, The University Of Texas System | Compounds with anti-tumor activity against cancer cells bearing HER2 exon 19 mutations |
| KR20210025064A (ko) | 2018-06-25 | 2021-03-08 | 스펙트럼 파마슈티컬즈 인크 | 항-her1, her2 또는 her4 항체와 포지오티닙의 조합물 및 이의 사용 방법 |
-
2019
- 2019-12-20 MX MX2021007554A patent/MX2021007554A/es unknown
- 2019-12-20 BR BR112021011493-9A patent/BR112021011493A2/pt not_active Application Discontinuation
- 2019-12-20 US US17/416,227 patent/US20220041751A1/en active Pending
- 2019-12-20 MA MA054559A patent/MA54559A/fr unknown
- 2019-12-20 JP JP2021535545A patent/JP7564806B2/ja active Active
- 2019-12-20 SG SG11202105736QA patent/SG11202105736QA/en unknown
- 2019-12-20 CA CA3121807A patent/CA3121807A1/en active Pending
- 2019-12-20 AU AU2019406210A patent/AU2019406210A1/en not_active Abandoned
- 2019-12-20 EP EP19899260.4A patent/EP3897650A4/en active Pending
- 2019-12-20 CN CN201980087140.8A patent/CN113271948B/zh active Active
- 2019-12-20 WO PCT/US2019/068153 patent/WO2020132633A1/en not_active Ceased
- 2019-12-20 KR KR1020217020491A patent/KR20210107023A/ko active Pending
-
2021
- 2021-05-31 PH PH12021551276A patent/PH12021551276A1/en unknown
- 2021-06-17 IL IL284162A patent/IL284162A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7265985B2 (ja) | Ｅｇｆｒまたはｈｅｒ２のエクソン２０変異を有するがん細胞に対する抗腫瘍活性を有する化合物 | |
| Prelaj et al. | Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: results from the expanded access program | |
| Kim et al. | Phase 1 studies of poziotinib, an irreversible pan-HER tyrosine kinase inhibitor in patients with advanced solid tumors | |
| JP2022527788A5 (https=) | ||
| Martinez-Useros et al. | The challenge of blocking a wider family members of EGFR against head and neck squamous cell carcinomas | |
| JP2022529016A5 (https=) | ||
| JP2022529945A5 (https=) | ||
| JP2022515128A5 (https=) | ||
| TW202529804A (zh) | 用於癌症治療的組合療法 | |
| CN111867586A (zh) | 用于治疗具有egfr激活突变的癌症的方法 | |
| WO2020030977A2 (en) | Methods and compositions for inhibition of egf/egfr pathway in cobination with anaplastic lymphoma kinase inhibitors | |
| AU2020391222A1 (en) | Combination therapy involving diaryl macrocyclic compounds | |
| JP2022527499A5 (https=) | ||
| Kim et al. | A phase II trial of nintedanib in patients with metastatic or recurrent head and neck squamous cell carcinoma: in-depth analysis of nintedanib arm from the KCSG HN 15-16 TRIUMPH trial | |
| JP2021519306A5 (https=) | ||
| Xie et al. | Amivantamab: a monoclonal EGFR-MET bispecific antibody for EGFR exon 20 insertion in non-small cell lung cancer | |
| US20210260064A1 (en) | Poziotinib combinations with an anti-her1, her2 or her4 antibody and methods of use thereof | |
| RU2020134932A (ru) | Соединения с противоопухолевой активностью против раковых клеток, несущих мутации в экзоне 19her2 | |
| CN107949401A (zh) | 联合施用酪氨酸激酶抑制剂来抑制表皮生长因子/表皮生长因子受体途径的方法及组合物 | |
| CN115698338A (zh) | 用妥卡替尼治疗her2突变型癌症的方法 | |
| Grellety et al. | A clinical case of invasive lobular breast carcinoma with ERBB2 and CDH1 mutations presenting a dramatic response to anti-HER2-directed therapy | |
| JP7334194B2 (ja) | Ｔｐ５３突然変異状態及び高頻度突然変異状態に基づくがん治療法 | |
| CN119604291A (zh) | Blu-945联合奥斯替尼治疗非小细胞肺癌 | |
| RU2021121207A (ru) | Комбинированная терапия для лечения рака | |
| JP2019123671A (ja) | 前立腺がんの予防又は治療剤 |